AAV: inAAVate™ Platform Infographic
OXB Investor Presentation June 2025
3 June 2025
Presentation: Accelerate Time to Clinic- A Platform and Analytics Approach
Enhancing Titers of Therapeutic Lentiviral Vectors using PKC Agonists
The 3 Rs Of Replication-Competent Lentivirus (RCL) Formation Risk: Real, Rare, or Artificial?
Optimising the Production of the 4th Generation Lentiviral Vector (LV) TetraVecta™ System: Towards Plug-and-Play LV Manufacturing
The Impact of Individual Helper Genes on AAV Productivity
Evaluation of Salt-Tolerant Endonucleases for Lentiviral Vector Purification
Enhancing Upstream Processes for High-Yield, High-Quality AAV Vector Production Using a Novel In-House Cell Line
Diving Deeper: Using a SYBR Gold Capsid Ejection Assay as an Orthogonal Method of Measuring Potency and VP1 Deamidation in AAV9 Drug Product Samples
Accelerate Time to Clinic: A Platform and Analytics Approach
Preliminary results for the year ended 31 December 2024
17 April 2025
